Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748461 | 1.00 | SRD5A2 (0.59) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| Clostebol SCHEMBL146712 | 0.82 | SHBG (0.76) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| Clostebol SCHEMBL4437252 | 0.82 | SHBG (0.76) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| Clostebol SCHEMBL216172 | 0.81 | SHBG (0.69) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| SCHEMBL3749010 | 0.80 | SRD5A2 (0.49) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| SCHEMBL216171 | 0.79 | SRD5A2 (0.61) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| SCHEMBL2251175 | 0.79 | SRD5A2 (0.61) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| SCHEMBL3749013 | 0.78 | SRD5A2 (0.48) | SRD5A2SHBGCYP19A1CYP3A4TSHR | |
| SCHEMBL6573064 | 0.77 | CYP3A4 (0.72) | CYP19A1CYP3A4TSHRTHPOHIF1A | |
| SCHEMBL6573070 | 0.77 | CYP3A4 (0.72) | CYP19A1CYP3A4TSHRTHPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | SRD5A2 15/4885SHBG 24/4885CYP19A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.